Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
PHILADELPHIA, Oct. 25, 2019 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE), a fully integrated, commercial gene therapy company dedicated to challenging the inevitability of genetic disease,...
-
Paralympic, blind skier declared Eye Want 2 Know® and pursued genetic testing to uncover the genetic cause of her retinitis pigmentosa (RP), an IRD Spark Therapeutics unveils enhanced ID YOUR IRD®...
-
PHILADELPHIA, Aug. 27, 2019 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE), a fully-integrated, commercial gene therapy company dedicated to challenging the inevitability of genetic disease,...
-
PHILADELPHIA, April 17, 2019 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ: ONCE), a fully integrated, commercial gene therapy company dedicated to challenging the inevitability of genetic disease,...
-
Roche to acquire Spark Therapeutics for $114.50 per share representing a total equity value of $4.8 billion Spark Therapeutics will continue its operations in Philadelphia as an independent company...
-
PHILADELPHIA, Feb. 19, 2019 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ: ONCE), a fully integrated, commercial gene therapy company dedicated to challenging the inevitability of genetic disease,...
-
PHILADELPHIA, Feb. 12, 2019 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ: ONCE), a fully integrated, commercial gene therapy company dedicated to challenging the inevitability of genetic disease,...
-
PHILADELPHIA, Jan. 31, 2019 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE), a fully integrated, commercial gene therapy company dedicated to challenging the inevitability of genetic disease,...
-
PHILADELPHIA, Jan. 02, 2019 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ: ONCE), a fully integrated, commercial gene therapy company dedicated to challenging the inevitability of genetic disease,...
-
Preliminary Phase 1/2 data for investigational SPK-8011 for hemophilia A show dramatic reductions in bleeds and infusions for first 12 participants with an encouraging safety profile, as of Nov. 2,...